Back to "Eyelid erythema remained significant, as..."
Claim
Strong Support
correlational
Analysis v3

In patients with mild Graves’ ophthalmopathy, taking 200 mcg of selenium daily for six months is associated with the absence of eyelid redness in all treated individuals, while 9.52% of untreated...

59
Pro
0
Against

Mechanism

Synthesis from 1 study

How it works

Selenium gets used to make proteins that remove harmful molecules in the eye area. This stops the chain reaction that causes swelling and redness, so the blood vessels stop leaking and the eyelids return to normal.

Most probable mechanism

In Simple Terms

Selenium enters the body and is used to make special proteins that clean up harmful molecules in the tissues around the eyes. These clean-up proteins reduce damage that triggers swelling and redness, which stops blood vessels from leaking and calming the inflammation in the eyelids.

Causal chain
1

Oral selenium is absorbed in the gastrointestinal tract and transported to orbital tissues via selenoprotein P

Supported by evidence
which leads to
2

Selenium is incorporated into selenoproteins including glutathione peroxidases and thioredoxin reductases in orbital fibroblasts and infiltrating immune cells

Supported by evidence
which leads to
3

Selenoproteins reduce hydrogen peroxide and lipid peroxides, lowering oxidative stress in orbital tissues

Supported by evidence
which leads to
4

Reduced oxidative stress inhibits activation of NF-κB and other pro-inflammatory signaling pathways in orbital fibroblasts

Supported by evidence
which leads to
5

Downregulation of pro-inflammatory cytokines including IL-6, TNF-α, and IFN-γ reduces recruitment and activation of T cells and macrophages in orbital fat and muscle

Supported by evidence
which leads to
6

Decreased inflammation reduces vascular permeability, edema, and tissue remodeling in orbital soft tissues, eliminating eyelid erythema

Verified by multiple studies

Evidence from Studies

Supporting (1)

59

Community contributions welcome

59

Effect of Selenium Supplementation on Mild Graves’ Ophthalmopathy at a Tertiary Hospital – a Six-Month, Open-Labelled, Assessor-Masked, Randomized Controlled Trial

Randomized Controlled Trial
Human

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Sign up to see full verdict

Source Study

Effect of Selenium Supplementation on Mild Graves’ Ophthalmopathy at a Tertiary Hospital – a Six-Month, Open-Labelled, Assessor-Masked, Randomized Controlled Trial

Score: 59
DOI: 10.35460/2546-1621.2025-0002

Similar Assertions

In patients with mild Graves’ ophthalmopathy, taking 200 mcg of selenium daily for six months is associated with a reduction in swelling of the eye tissues and improved clinical activity scores compared to those not taking selenium.

59
0
90%

Taking 200 micrograms of selenium daily for six months increases the percentage of adults with mild Graves’ ophthalmopathy who achieve no active inflammation, from one-third to just over six in ten, compared to those using only eye drops.

53
0
90%

In adults with mild Graves’ ophthalmopathy, taking selenium supplements for six months results in a measurable reduction in swelling of the caruncle and plical tissues compared to standard care alone.

53
0
88%

In patients with mild, active Graves' orbitopathy lasting less than seven months, selenium supplementation may be linked to better quality of life and fewer eye symptoms, but these findings are based on one study and have not been confirmed by others.

39
0
87%

Among adult Filipino patients with mild Graves’ ophthalmopathy lasting less than 18 months, taking 200 micrograms of selenium daily for six months along with standard eye care results in 61.9% of eyes reaching a clinical activity score of 0 at six months, compared to 33.3% in those not taking selenium.

59
0
86%